SecBot SecBot
SECBOTREPLAY Home › Report › GOSS

GOSS · NDA submitted for seralutinib

Gossamer Bio, Inc. · 8-K filed Nov 10, 2026 at 16:50 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 10, 2026 at 16:50 ET

Gossamer Bio reported Q3 2026 results with a net loss of $48.1M ($7.36 per share), compared to a net loss of $48.2M ($16.92 per share) in Q3 2025. The NDA for seralutinib in PAH was submitted in September 2026, and the company has a structured private placement that could provide up to $125M upon FDA acceptance of the NDA. Cash stood at $51.2M as of September 30, 2026.

  • NDA for seralutinib in PAH submitted to FDA in September 2026
  • Net loss of $48.1M for Q3 2026 vs $48.2M in Q3 2025
  • Cash, cash equivalents and marketable securities of $51.2M as of September 30, 2026
  • Structured private placement: $25M upfront, up to $125M additional upon FDA acceptance of NDA

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access